JP Patent

JP2022186979A — エラバサイクリンの結晶形

Assigned to Tetraphase Pharmaceuticals Inc · Expires 2022-12-15 · 3y expired

What this patent protects

【課題】エラバサイクリンの結晶形を提供すること。【解決手段】所定の構造式１で表される化合物のビスＨＣｌ塩の結晶形。【選択図】なし

USPTO Abstract

【課題】エラバサイクリンの結晶形を提供すること。【解決手段】所定の構造式１で表される化合物のビスＨＣｌ塩の結晶形。【選択図】なし

Drugs covered by this patent

Xerava (ERAVACYCLINE DIHYDROCHLORIDE) · Tetraphase Pharms

Patent Metadata

Patent number: JP2022186979A
Jurisdiction: JP
Classification: —
Expires: 2022-12-15
Drug substance claim: No
Drug product claim: No
Assignee: Tetraphase Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.